Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Avacopan in Healthy Japanese and Caucasian Males
NCT05988008Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) (4 arms), sponsored by Amgen. Primary endpoints: Number of Participants Experiencing Adverse Events up to 14 days, Number of Participants Experiencing Adverse Drug Reactions up to 14 days and 13 more. Started Oct 2017; status: completed.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05988008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988008.